UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

The Lancet (British edition), 2022-01, Vol.399 (10320), p.161-171

2022

Volltextzugriff (PDF)

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

The lancet oncology, 2014-10, Vol.15 (11), p.1195-1206

2014

Volltextzugriff (PDF)

Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma

Journal of clinical oncology, 2013-10, Vol.31 (29), p.3696-3703

2013

Volltextzugriff (PDF)

Association of digital measures and self-reported fatigue: a remote observational study in healthy participants and participants with chronic inflammatory rheumatic disease

Frontiers in digital health, 2023-06, Vol.5, p.1099456-1099456

2023

Volltextzugriff (PDF)

Patient‐reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double‐blind, placebo‐controlled PANORAMA‐1 trial

British journal of haematology, 2018-06, Vol.181 (5), p.628-636

2018

Volltextzugriff (PDF)

Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study

The Lancet (British edition), 2024-08, Vol.404 (10452), p.540-553

2024

Volltextzugriff (PDF)

Ex vivo skin absorption of terpenes from Vicks VapoRub ointment

Medical science monitor, 2008-08, Vol.14 (8), p.PI19-PI23

2008

Volltextzugriff (PDF)

Patient reported outcomes (PROs) of multiple myeloma (MM) patients treated with panobinostat (PAN) after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled, PANORAMA-1 trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.8054-8054

2016

Volltextzugriff (PDF)

Tremendous ex vivo child skin absorption and permeation of eucalyptol

Journal of dermatological science, 2008-11, Vol.52 (2), p.139-140

2008

Volltextzugriff (PDF)

Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial

British journal of haematology, 2017-10, Vol.179 (1), p.66-74

2017

Volltextzugriff (PDF)

Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8526-8526

2015

Volltextzugriff (PDF)

Analysis of outcomes based on response for patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 PANORAMA 1 study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8575-8575

2015

Volltextzugriff (PDF)

Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8510-8510

2014

Volltextzugriff (PDF)

Middle cerebral artery occlusion produces secondary, remote impairment in hippocampal plasticity of rats – involvement of N-methyl- d-aspartate receptors?

Neuroscience letters, 2000-03, Vol.281 (2), p.143-146

2000

Volltextzugriff (PDF)

Neuroprotective effects of NS-7, voltage-gated Na+/Ca2+ channel blocker in a rodent model of transient focal ischemia

Neurotoxicity research, 2002-01, Vol.4 (7-8), p.655-661

2002

Volltextzugriff (PDF)

Neuroprotective effects of NS-7, voltage-gated Na/Ca channel blocker in a rodent model of transient focal ischemia

Neurotoxicity research, 2002-01, Vol.4 (7-8), p.655-661

2002

Volltextzugriff (PDF)

Neuroprotective effects of NS-7, voltage-gated Na+/Ca2+ channel blocker in a rodent model of transient focal ischaemia

Neurotoxicity research, 2002-11, Vol.4 (7-8), p.655

2002

Volltextzugriff (PDF)

Neuroprotective activity of a nanoparticulate formulation of the glycineB site antagonist MRZ 2/576 in transient focal ischaemia in rats

Arzneimittel-Forschung, 2002, Vol.52 (3), p.168

2002

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Female
(8)
Humans
(8)
Male
(8)
Adult
(7)
Middle Aged
(7)
Aged
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Multiple Myeloma - Drug Therapy
(5)
Treatment Outcome
(5)
Bortezomib
(4)
Hematology
(4)
Hydroxamic Acids - Administration & Dosage
(4)
Indoles - Administration & Dosage
(4)
Panobinostat
(4)
Patients
(4)
Quality Of Life
(4)
Biological And Medical Sciences
(3)
Dexamethasone - Administration & Dosage
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma

Association of digital measures and self-reported fatigue: a remote observational study in healthy participants and participants with chronic inflammatory rheumatic disease

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

Patient‐reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double‐blind, placebo‐controlled PANORAMA‐1 trial

Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study

Ex vivo skin absorption of terpenes from Vicks VapoRub ointment

Patient reported outcomes (PROs) of multiple myeloma (MM) patients treated with panobinostat (PAN) after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled, PANORAMA-1 trial

Tremendous ex vivo child skin absorption and permeation of eucalyptol

Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial

Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment

Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1

Analysis of outcomes based on response for patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 PANORAMA 1 study

Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study

Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma

Middle cerebral artery occlusion produces secondary, remote impairment in hippocampal plasticity of rats – involvement of N-methyl- d-aspartate receptors?

Neuroprotective effects of NS-7, voltage-gated Na+/Ca2+ channel blocker in a rodent model of transient focal ischemia

Neuroprotective effects of NS-7, voltage-gated Na/Ca channel blocker in a rodent model of transient focal ischemia

Neuroprotective effects of NS-7, voltage-gated Na+/Ca2+ channel blocker in a rodent model of transient focal ischaemia

Neuroprotective activity of a nanoparticulate formulation of the glycineB site antagonist MRZ 2/576 in transient focal ischaemia in rats

Suchergebnisse filtern